Recombinant Glycoprotein E of Varicella Zoster Virus Contains Glycan-Peptide Motifs That Modulate B Cell Epitopes into Discrete Immunological Signatures

International Journal of Molecular Sciences
Rickard NordénTomas Bergström

Abstract

A recombinant subunit vaccine (Shingrix®) was recently licensed for use against herpes zoster. This vaccine is based on glycoprotein E (gE) of varicella zoster virus (VZV), the most abundantly expressed protein of VZV, harboring sites for N- and O-linked glycosylation. The subunit vaccine elicits stronger virus-specific CD4+ T cell response as well as antibody B cell response to gE, compared to the currently used live attenuated vaccine (Zostavax®). This situation is at variance with the current notion since a live vaccine, causing an active virus infection, should be far more efficient than a subunit vaccine based on only one single viral glycoprotein. We previously found gE to be heavily glycosylated, not least by numerous clustered O-linked glycans, when it was produced in human fibroblasts. However, in contrast to Zostavax®, which is produced in fibroblasts, the recombinant gE of Shingrix® is expressed in Chinese hamster ovary (CHO) cells. Hence, the glycan occupancy and glycan structures of gE may differ considerably between the two vaccine types. Here, we aimed at (i) defining the glycan structures and positions of recombinant gE and (ii) identifying possible features of the recombinant gE O-glycosylation pattern contribu...Continue Reading

References

Mar 14, 2003·Glycobiology·Kelly G Ten HagenLawrence A Tabak
Jun 3, 2005·The New England Journal of Medicine·M N OxmanUNKNOWN Shingles Prevention Study Group
Dec 21, 2005·Virology·Tim Dudek, David M Knipe
Aug 13, 2008·Glycoconjugate Journal·E Tian, Kelly G Ten Hagen
Apr 21, 2009·Nature Methods·Jacek R WiśniewskiMatthias Mann
Jun 10, 2010·Nature Biotechnology·Adam S LauringRaul Andino
Dec 15, 2010·Trends in Cell Biology·David J GillFrederic Bard
Aug 2, 2011·Nature Biotechnology·Xun XuJun Wang
Feb 1, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Kenneth E SchmaderJanie Parrino
Aug 6, 2014·Molecular & Cellular Proteomics : MCP·Zhang YangHenrik Clausen
Mar 19, 2015·The Journal of Infectious Diseases·Kerry J LaingDavid M Koelle
Apr 29, 2015·The New England Journal of Medicine·Himal LalUNKNOWN ZOE-50 Study Group
Nov 3, 2015·Reviews in Medical Virology·Sigvard OlofssonHans H Wandall
Apr 30, 2016·The Journal of Biological Chemistry·Ieva BagdonaiteHans H Wandall
Sep 15, 2016·The New England Journal of Medicine·Anthony L CunninghamUNKNOWN ZOE-70 Study Group
Dec 17, 2016·Virology·Amanda L CollarSteven B Bradfute
Sep 22, 2017·Journal of Virology·Arun S AnnamalaiAsit K Pattnaik
Jul 10, 2018·PLoS Neglected Tropical Diseases·Amanda FritzenOla Blixt
Jul 20, 2018·The Journal of Clinical Investigation·Myron J LevinAdriana Weinberg
Sep 25, 2018·The Journal of Infectious Diseases·Adriana WeinbergMyron J Levin
Nov 16, 2018·Parasites & Vectors·Pavlina VechtovaLibor Grubhoffer

❮ Previous
Next ❯

Methods Mentioned

BETA
glycosylation
ELISA
enzymatic treatments
PCR
protein assay
Fusion Tribrid

Software Mentioned

Find
Expasy
Mascot distiller
Scanarray Express
Mascot
GraphPad

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Related Papers

Biologicals : Journal of the International Association of Biological Standardization
A A Gershon, S Silverstein
Human Vaccines & Immunotherapeutics
Myron J Levin, Adriana Weinberg
Advances in Biotechnological Processes
B Morein, S Höglund
© 2022 Meta ULC. All rights reserved